The May 31, 2026 PDUFA date for CTx-1301 is the primary catalyst — approval would transform the company from pre-revenue to commercial stage, while a CRL would likely trigger significant dilution or restructuring. The recent S-3 shelf registration adds overhang risk from potential secondary sales by existing investors. Monitor FDA communication closely in the next two weeks.
Price Chart
Executive Summary
Cingulate Inc. reported Q1 2026 results with a net loss of $9.3M, widening from a $3.9M loss in Q1 2025, driven by a 287% increase in G&A expenses to $5.7M as the company builds commercial infrastructure ahead of the May 31, 2026 PDUFA date for CTx-1301. Cash grew to $25.9M from $11.0M at year-end 2025, funded by a $12M PIPE and ATM usage, extending runway into 2027. The pre-revenue biotech remains a binary event stock with no revenue or EPS consensus to beat.
Key Facts
- Net loss widened to $9.3M in Q1 2026 from $3.9M in Q1 2025, driven by G&A costs rising 287% to $5.7M for commercial build-out
- Cash and cash equivalents grew to $25.9M as of March 31, 2026, up $14.9M from $10.95M at December 31, 2025
- Working capital improved to $17.0M from $1.7M at year-end 2025
- R&D expenses were $2.2M, down 1.8% YoY as clinical studies concluded, offset by higher regulatory/manufacturing costs
- Cash runway extended into 2027, supporting operations through the May 31, 2026 PDUFA date for CTx-1301
- S-3 shelf registration filed April 14, 2026 for resale of up to 4,208,711 shares from a January 2026 private placement
- No revenue generated; pre-revenue clinical-stage biotech with no analyst EPS consensus available
Financial Impact
Net loss of $9.3M in Q1 2026 vs $3.9M in Q1 2025; cash position $25.9M; no revenue
Risk Factors
- PDUFA date of May 31, 2026 — FDA could issue a Complete Response Letter (CRL) on CTx-1301 NDA, given ongoing CMC information requests
- S-3 shelf registration filed April 14, 2026 allows selling stockholders to resell up to 4.2M shares, creating overhang
- Pre-revenue with no approved products; net loss widening as commercial spending ramps up
- Accumulated deficit of $141.7M with no path to profitability without product approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-022881 |
| Exhibit: ex99-1.htm | 0001493152-26-022881 |
| Document: 0001493152-26-022881-index-headers.html | 0001493152-26-022881 |
| Document: 0001493152-26-022881-index.html | 0001493152-26-022881 |
| Document: 0001493152-26-022881.txt | 0001493152-26-022881 |
| 8-K Data (Synthetic) | 0001493152-26-022881 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 2, 2026 20w ago | 8-K | $0.0601 $0.0114 | ▲ +81.03% | ▲ +82.15% | — |
May 19, 2026 22w ago | 8-K | $0.0601 $0.007200 | ▼ −88.02% | ▼ −93.02% | — |
May 14, 2026 23w ago | 8-K | $0.0601 $0.007200 | ▼ −88.02% | ▼ −91.61% | — |
May 14, 2026 23w ago | Press Release | $0.0601 $0.007200 | ▼ −88.02% | ▼ −91.61% | — |
Apr 27, 2026 26w ago | EFFECT | $0.0601 $0.0189 | ▲ +68.55% | ▲ +73.33% | — |
Mar 18, 2026 31w ago | Press Release | $0.0601 $0.0601 | · 0.00% | ▼ −11.53% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers